Compare CLST & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | LUNG |
|---|---|---|
| Founded | 1922 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 57.9M |
| IPO Year | 2021 | 2020 |
| Metric | CLST | LUNG |
|---|---|---|
| Price | $15.87 | $1.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 5.4K | ★ 538.0K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | 7.64 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $28.34 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $11.62 | $1.13 |
| 52 Week High | $18.16 | $3.88 |
| Indicator | CLST | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 45.70 |
| Support Level | $15.20 | $1.19 |
| Resistance Level | $15.97 | $1.45 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 5.00 | 37.04 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.